Twenty-five years survival of primary central nervous system lymphomas treated with the C5R regimen
Authors:
- Jean-Yves BlayJBJean-Yves Blay
- Sylvain LamureSLSylvain Lamure
- Waisse WaissiWWWaisse Waissi
- Marie-Pierre SunyachMSMarie-Pierre Sunyach
- Haifa BahriHBHaifa Bahri
- Philippe ReyPRPhilippe Rey
- Catherine Chassagne-ClementCCCatherine Chassagne-Clement
- Emmanuelle Nicolas-VirelizierENEmmanuelle Nicolas-Virelizier
- Amine BelhabriABAmine Belhabri
- Yann GuillerminYGYann Guillermin
- Pierre BironPBPierre Biron
- Catherine SebbanCSCatherine Sebban
- 30 August 2026
- journal article
- Published by Elsevier in European Journal of Cancer
- Vol. 247
Abstract
No abstract availableFunding Information
- Institut National Du Cancer
- European Commission
This publication has 25 references indexed in Scilit:
- Clinical characteristics and survival outcomes of patients with primary central nervous system lymphoma treated with high-dose methotrexate-based polychemotherapy and consolidation therapiesEuropean Journal of Cancer, 2024
- Primary central nervous system lymphomaNature Reviews Disease Primers, 2023
- European Association of Neuro-Oncology (EANO) guidelines for treatment of primary central nervous system lymphoma (PCNSL)Neuro-Oncology, 2022
- Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trialLeukemia, 2022
- Second primary cancers: a retrospective analysis of real world data using the enhanced medical research engine ConSoRe in a French comprehensive cancer centerInternational Journal of Clinical Oncology, 2021
- Rituximab in primary central nervous system lymphoma—A systematic review and meta‐analysisHematological Oncology, 2019
- Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trialThe Lancet Haematology, 2017
- Utility of post-therapy brain surveillance imaging in the detection of primary central nervous system lymphoma relapseEuropean Journal of Cancer, 2017
- High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trialThe Lancet Oncology, 2010
- Long-term follow-up of an age-adapted C5R protocol followed by radiotherapy in 99 newly diagnosed primary CNS lymphomas: a prospective multicentric phase II study of the Groupe d’Etude des Lymphomes de l’Adulte (GELA)Annals of Oncology, 2009